Edit Symbol List
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
EnzonPharmaceuticals, Inc. Common Stock Intraday Chart
|Intraday||Last 52 Weeks|
|High||$ 0.51||$ 1.82|
|Low||$ 0.50||$ 0.39|
The current last sale of $0.5099 is 30.74% Higher thanthe 52 week low.
|Ex Dividend Date The data is based on historical ex-dividend data & doesn't include upcoming values. Visit the dividend history page to see the upcoming dividend information.||N/A|
|Dividend Payment Date||N/A|
|Current Yield Indicated yield represents annual dividends divided by current stock price. The data is based on historical ex-dividend data & doesn't include upcoming values. Visit the dividend history page to see the upcoming dividend information.||0 %|
|Special Dividend||$ 0.25|
|Special Dividend Date||Dec. 30, 2015|
|Special Dividend Payment Date||Dec. 29, 2015|
Company Description (as filed with the SEC)
Enzon Pharmaceuticals, Inc. (together with its subsidiaries, the "Company," "we" or "us") receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products, namely, PegIntron ®, Sylatron ®, Macugen ® and CIMZIA ®. We also had previously received royalty revenues from licensing arrangement related to sales of Oncaspar and Adagen until our rights to receive royalties on sales of these products expired in 2014. In addition, our rights to receive royalties on sales of Macugen and CIMZIA expired in the U.S. and Great Britain in 2014. The primary source of our royalty revenues is sales of PegIntron, which is marketed by Merck & Co., Inc. ("Merck"). We currently have no clinical operations and limited corporate operations. We have no intention of resuming any clinical development activities or acquiring new sources of royalty revenues. ... More ...